Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden

Journal of Medical Economics

Volumn 13, Issue 3, 2010, Pages 516-526

  Nordström, Göran ^a   Despiegel, Nicolas ^b   Marteau, Florence ^b   Danchenko, Natalya ^b   Maman, Khaled ^c  

^a Psykiatriska Kliniken   (Sweden)

^b Lundbeck   (France)

^c Altipharm   (France)

Author keywords

Cost effectiveness; Major depressive disorder (MDD); Remission; Second step therapy; Selective serotonin reuptake inhibitor (SSRI); Serotonin norepinephrine reuptake inhibitor (SNRI)

Indexed keywords

DULOXETINE; ESCITALOPRAM; VENLAFAXINE;

ARTICLE; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; EJACULATION DISORDER; FATIGUE; HEADACHE; HEALTH CARE COST; HUMAN; INSOMNIA; MAJOR DEPRESSION; NAUSEA; QUALITY ADJUSTED LIFE YEAR; REMISSION; SIDE EFFECT; SOMNOLENCE; SWEATING; SWEDEN; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; CYCLOHEXANOLS; DECISION SUPPORT TECHNIQUES; DEPRESSIVE DISORDER, MAJOR; HUMANS; MARKOV CHAINS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; SWEDEN; THIOPHENES;

EID: 77956689524     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.506371     Document Type: Article

References (30)

1. Mattisson C, Bogren M, Nettelbladt P, et al. First incidence depression in the Lundby Study: a comparison of the two time periods 1947-1972 and 1972-1997. J Affect Disord 2005;87:151-160
2. Nordstrom A, Bodlund O. Every third patient in primary care suffers from depression, anxiety or alcohol problems. Nord J Psychiatry 2008;62:250
3. Sobocki P, Lekanderl, Borgstrom F, et al.The economic burden of depression in Sweden from 1997-2005. Eur Psychiatry 2007;22:146-152
4. Gelenberg AJ, Hopkins HS. Assessing and treating depression in primary care medicine. Am J Med 2007;120:105-108
5. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-1252
6. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157:1-45
7. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22:343-396. Epub 2008 Apr 15
8. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venla-faxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-1242
9. Ruhe HG, Huyser J, Swinkels JA, et al. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006;67:1836-1855. Review (Pubitemid 46055194)
10. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within-versus across-class switches. Biol Psychiatry 2008;63:699-704
11. Rush AJ. STAR*D: what have we learned? Am J Psychiatry 2007; 164:201-204
12. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001;50:345-350
13. Lam RW, Larsson LonnS, Despiegel N. Escitalopram versus SNRIs as second-line treatment. Int J Psychiatry Clin Pract 2009;13(Suppl 1):35-36
14. Armstrong EP, Skrepnek GH, Erder MH. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. Curr Med Res Opin 2007;23:251-258
15. Khan A, Bose A, Alexopoulos CG, et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Invest 2007;27:481-492
16. Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007;23: 1605-1614
17. Bielski RJ, Ventura D, Chang C-C. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1190-1196
18. Montgomery SA, Huusom AKT, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50:57-64
19. Wade AG, Milea D, Despiegel N, et al.AGPRD-based comparison of second-line antidepressant therapy with escitalopram and venlafaxine. Presented at the ISPOR 11th Annual European Congress, Athens, Greece, 8-11 November, 2008
20. Wade AG, Milea D, Despiegel N, et al. A comparison of second-line antidepressant therapy with escitalopram and venlafaxine in the UK based on the General Practitioners Research Database. Clin Ther In press
21. Benedict A, Arellano J, De Cock E, et al. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland. J Affect Disord 2009; 120:94-104
22. Sobocki P, Ekman M, Agren H, et al. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract 2006;60:791-798
23. Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004;18:911-932
24. MEPS, 2003: Agency for Healthcare Research and Quality, Center for Cost and Financing Studies. MEPS HC-052. 2000 medical conditions, June 2003 [online]. Available from URL: http://www.meps.ahrq.gov/PUFFiles/H52/H52doc.htm [Accessed (2003) Nov 10]
25. National Institute for Clinical Excellence: Guide to the Methods of Technology Appraisal, April 2004. Available from URL: http://www.nice.org.uk/ niceMedia/pdf/TAP-Methods.pdf [Accessed Aug 2009]
26. Croom KF, Plosker GL. A pharmacoeconomic review of its use in depression. Pharmaeconomics 2003;21:1185-1209
27. Llorca PM, Fernandez JL. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost effectiveness vs. venlafaxine extended-release formulation. Int J Clin Pract 2007; 61:702-710
28. Fernandez J-L, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005;23:155-167
29. Malone DC. A budget-impact and cost-effectiveness model for second-line treatment of major depression. J Manag Care Pharm 2007;13 (6SupplA):S8-18
30. Wade AG, Fernandez JL, Francois C, et al. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data. Pharmaeconomics 2008;26:969-981